Zhang, Tao http://orcid.org/0009-0004-1704-1455
Xu, Daichao http://orcid.org/0000-0002-3286-4968
Liu, Jianping http://orcid.org/0000-0001-7090-2112
Wang, Min
Duan, Li-Juan
Liu, Min
Meng, Huyan http://orcid.org/0000-0003-1511-6156
Zhuang, Yuan
Wang, Huibing
Wang, Yingnan
Lv, Mingming http://orcid.org/0000-0003-4401-7464
Zhang, Zhengyi http://orcid.org/0000-0002-9885-0817
Hu, Jia
Shi, Linyu
Guo, Rui
Xie, Xingxing
Liu, Hui
Erickson, Emily
Wang, Yaru http://orcid.org/0000-0001-8300-0847
Yu, Wenyu
Dang, Fabin http://orcid.org/0000-0002-1954-8231
Guan, Dongxian
Jiang, Cong
Dai, Xiaoming http://orcid.org/0000-0001-9671-8137
Inuzuka, Hiroyuki
Yan, Peiqiang
Wang, Jingchao
Babuta, Mrigya http://orcid.org/0000-0001-8420-4796
Lian, Gewei
Tu, Zhenbo http://orcid.org/0000-0002-3720-7844
Miao, Ji http://orcid.org/0000-0003-0869-4492
Szabo, Gyongyi
Fong, Guo-Hua
Karnoub, Antoine E.
Lee, Yu-Ru http://orcid.org/0000-0001-6592-6806
Pan, Lifeng http://orcid.org/0000-0002-9229-6288
Kaelin, William G. Jr. http://orcid.org/0000-0002-0574-4856
Yuan, Junying http://orcid.org/0000-0003-2405-6036
Wei, Wenyi http://orcid.org/0000-0003-0512-3811
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35CA253027)
Article History
Received: 30 December 2021
Accepted: 21 May 2023
First Online: 3 July 2023
Competing interests
: W.W. is a co-founder and consultant for Rekindle Therapeutics. G.S. is paid consultant for Cyta Therapeutics, DURECT, Evive, Merck, Pfizer, Surrozen, Terra Firma, Pandion Therapeutics, Labcorp, Glympse Bio, Satellite Bio and Zomagen. The remaining authors declare no competing interests.